Lineage Cell Therapeutics (XTAE:LCTX) Receivables Turnover : 3.51 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lineage Cell Therapeutics's Revenue for the three months ended in Mar. 2024 was ₪5.37 Mil. Lineage Cell Therapeutics's average Accounts Receivable for the three months ended in Mar. 2024 was ₪1.53 Mil. Hence, Lineage Cell Therapeutics's Receivables Turnover for the three months ended in Mar. 2024 was 3.51.

Lineage Cell Therapeutics Receivables Turnover Historical Data

The historical data trend for Lineage Cell Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Receivables Turnover Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

2.73

4.82

0.15

0.58

17.17

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															9.54	9.98	2.85	3.55	3.51

Competitive Comparison of Lineage Cell Therapeutics's Receivables Turnover

For the Biotechnology subindustry, Lineage Cell Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Receivables Turnover falls into.

Lineage Cell Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Lineage Cell Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	33.251	/ (	(1.104	+	2.769)	/	2 )
=	33.251	/	1.9365
=	17.17

Lineage Cell Therapeutics's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	5.368	/ (	(2.769	+	0.286)	/	2 )
=	5.368	/	1.5275
=	3.51

Lineage Cell Therapeutics (XTAE:LCTX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Lineage Cell Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.